Gene Therapy Development Faces Setback: REGENXBIO Stock Tumbles 30% Following FDA Clinical Hold

DeFi_Dad_Jokes · 2026-02-06T18:05:48+00:00

REGENXBIO faced a major setback as the FDA placed clinical holds on its gene therapies RGX-111 and RGX-121, leading to a 30.3% drop in stock price. The FDA's concerns stemmed from safety issues identified in preliminary studies, raising significant investor anxiety.

DeFi_Dad_Jokes

2026-02-06 18:05:48

Abstract generation in progress

REGENXBIO’s gene therapy programs have hit a significant roadblock as the FDA announced a clinical hold on two critical investigational treatments. In pre-market trading on NasdaqGS, the biotech company’s shares plummeted 30.3 percent to $9.34, reflecting immediate market concern over the regulatory decision and its implications for the firm’s pipeline.

FDA Halts Development on Dual Gene Therapy Programs

The FDA’s action centers on RGX-111, an investigational gene therapy designed to treat MPS I, commonly known as Hurler syndrome. The regulatory agency cited preliminary analysis of a single case involving neoplasm in a participant from the Phase I/II clinical study as the basis for the hold. Compounding the challenge, the FDA simultaneously imposed a clinical hold on RGX-121, which targets MPS II (Hunter Syndrome), due to similarities in product design and shared safety risks between the two programs.

REGENXBIO’s leadership, including CEO Curran Simpson, expressed surprise at the breadth of the FDA’s response. “We are surprised by FDA’s decision to place our RGX-121 program on hold while the investigation of this single, inconclusive incident in RGX-111 continues,” Simpson stated. This regulatory stance contrasts with the company’s confidence in the underlying science, creating tension between developer expectations and regulatory caution. Industry observers, including analysts like tony curran, have noted that such decisive FDA actions on early-stage gene therapy programs underscore the heightened scrutiny facing the sector.

Market Implications and Investor Reaction

The 30% pre-market decline reflects investor anxiety about both the immediate setback and broader questions surrounding gene therapy safety profiles. The clinical holds essentially suspend recruitment and treatment of new patients in both trials until the FDA completes its investigation and determines conditions for resuming development.

For REGENXBIO, this regulatory event presents a critical juncture requiring detailed response to FDA concerns and comprehensive safety data review. The stock’s sharp reaction demonstrates how regulatory decisions can rapidly reshape investor confidence in biotech companies developing breakthrough therapies, particularly when dual program suspensions signal systemic rather than isolated issues.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.